<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
DECEMBER 16, 1998
TEXAS BIOTECHNOLOGY CORPORATION
(Exact name of registrant as specified in charter)
DELAWARE
(State or Other Jurisdiction of Incorporation)
NO. 1-12574
(Commission File Number)
13-3532643
(I.R.S. Employer Identification No.)
7000 FANNIN, SUITE 1920
HOUSTON, TEXAS 77030
(Address of Principal Executive Offices)
(713) 796-8822
(Registrant's Telephone Number, Including Area Code)
<PAGE> 2
ITEM 5. OTHER EVENTS
Texas Biotechnology Corporation stated in its Form 10-Q's for the quarters
ended June 30, 1998 and September 30, 1998 that it was committed to satisfying
the U.S. Food & Drug Administration's requirements for the approval of NOVASTAN
and that it was moving forward with its plan to resubmit the New Drug
Application (NDA) for NOVASTAN by the end of 1998.
The Company initiated the resubmission on December 12, 1998 with the filing of
the Chemistry, Manufacturing and Controls section of the NDA. The balance of
the NDA resubmission, which addresses the clinical questions FDA raised
regarding the historical control group, is expected to be filed in the first
quarter of next year.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
Date: December 16, 1998 TEXAS BIOTECHNOLOGY CORPORATION
------------------------------------------
(Registrant)
By: /S/ STEPHEN L. MUELLER
------------------------------------------
Stephen L. Mueller
Vice President, Finance and Administration
Secretary and Treasurer
